There is a rationale for clinical trials to evaluate the potential benefits of IGF-1 replacement in very preterm infants.
No takes yet. Share an insight, caveat, or question.
Hellström et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: